Epiomic Epidemiology Series: Pulmonary Hypertension Forecast in 8 Major Markets 2015-2025

August 2015 | 50 pages | ID: E2162034104EN
Black Swan Analysis limited

Abstracts

Pulmonary Hypertension (PH) is a condition in which pulmonary arterial pressure is 25 mmHg or greater, measured via a cardiac catheterisation. There is a number of underlying causes for this syndrome and can be groups into different classifications according to the Dana Point. This report provides the current prevalent population for PH across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of the types, occlusion locations and the prevalence of associated disorders of PH. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of PH have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for PH include:

• COPD
• Fibrotic Diseases
• Cardiovascular Diseases
  • Valvular Dysfunction
  • Congenital Heart Disease
• Diabetes
• Thyroid Disease
• Deep Vein Thrombosis (DVT) and Thrombotic Events
• Obstructive Sleep Apnoea (OSA)
• Schistosomiasis

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global PH’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of PH and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on PH’s prevalent population.
• Identify sub-populations within PH which require treatment.
• Gain an understanding of the specific markets that have the largest number of PH patients.

Contents

Introduction
Cause of the Disease
Risk Factors and Prevention
Diagnosis of the Disease
  Haemodynamic definitions of Pulmonary Hypertension
Variation by Geography /Ethnicity
Disease Prognosis and Clinical Course
Key Co-Morbid Conditions / Features Associated with the Disease
Methodology for Quantifications of Patient Number
  Additional Data Available on Request
Top Line Prevalence for Pulmonary Hypertension
PH by Dana Point Classification Grouping
  PH by Dana Point Grouping
Pulmonary Arterial Hypertension
  PAH caused by Portopulmonary Hypertension
  PAH caused by Congenital Heart Disease
  PAH caused by Connective Tissue Disease
  Significant Co-morbid Conditions Associated with PAH
Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
  CTEPH by NYHA Functional Class
  CTEPH by Operable Status
  Significant Co-morbid Conditions Associated with CTEPH
Abbreviations and Acronyms used in the Report
Other Black Swan Analysis Publications
Patient Based Offering
Online Pricing Data and Platforms
References
Appendix

List Of Tables

LIST OF TABLES & FIGURES

Dana Point Clinical Classification of Pulmonary Hypertension
Haemodynamic Definitions of Pulmonary Hypertension
Functional Classification of Pulmonary Hypertension by NYHA Class
Prevalence of PH, total (000s)
Prevalence of PH, males (000s)
Prevalence of PH, females (000s)
PH by Main DANA Grouping, total (000s)
PAH by NYUHA Class at Presentation, total (000s)
PAH by Underlying Aetiology, total (000s)
PAH – Severity of Right Ventricle Enlargement (000s)
Idiopathic PAH by NYHA class, total (000s)
Portopulmonary Hypertension by NYHDA Class, total (000s)
PAH Caused by Congenital Heart Disease by NYHDA class, total (000s)
PAH Caused by Connective Tissue Disease by NYHDA class, total (000s)
Prevalence of Hypertension in Patients with PAH, total (000s)
Prevalence of Diabetes in Patients with PAH, total (000s)
Prevalence of Ischemic Heart Disease in Patients with PAH, total (000s)
Prevalence of Thyroid Disease in Patients with PAH, total (000s)
Prevalence of Obstructive Sleep Apnoea in Patients with PAH, total (000s)
Prevalence of Obstructive Airway Disease in Patients with PAH, total (000s)
CTEPH by NYHA class, total (000s)
CTEPH Patients by Operable Status, total (000s)
Prevalence of COPD in Patients with CTEPH, total (000s)
Prevalence of Thrombophilic Disorder in Patients with CTEPH, total(000s)
Prevalence of Varicose Veins in Patients with CTEPH, total (000s)
Prevalence of Confirmed Previous Acute PE in Patients with CTEPH, total (000s)
Abbreviations and Acronyms used in the Report
USA Prevalence of PH by 5-yr age cohort, males (000s)
USA Prevalence of PH by 5-yr age cohort, females (000s)
France Prevalence of PH by 5-yr age cohort, males (000s)
France Prevalence of PH by 5-yr age cohort, females (000s)
Germany Prevalence of PH by 5-yr age cohort, males (000s)
Germany Prevalence of PH by 5-yr age cohort, females (000s)
Italy Prevalence of PH by 5-yr age cohort, males (000s)
Italy Prevalence of PH by 5-yr age cohort, females (000s)
Spain Prevalence of PH by 5-yr age cohort, males (000s)
Spain Prevalence of PH by 5-yr age cohort, females (000s)
United Kingdom Prevalence of PH by 5-yr age cohort, males (000s)
United Kingdom Prevalence of PH by 5-yr age cohort, females (000s)
Brazil Prevalence of PH by 5-yr age cohort, males (000s)
Brazil Prevalence of PH by 5-yr age cohort, females (000s)
Japan Prevalence of PH by 5-yr age cohort, males (000s)
Japan Prevalence of PH by 5-yr age cohort, females (000s)